文献速递肺栓塞与肺血管病

肺动脉高压一氧化氮通路靶向药物安全性比较:临床试验荟萃分析与WHO药物警戒数据库失衡分析

Comparative Safety of Drugs Targeting the Nitric Oxide Pathway in Pulmonary Hypertension: A Mixed Approach Combining a Meta-Analysis of Clinical Trials and a Disproportionality Analysis From the World Health Organization Pharmacovigilance Database.
PubMed 文献 · Chest · 2017-12-21

该研究结合随机对照试验安全性荟萃分析与WHO VigiBase药物警戒数据库失衡分析,比较西地那非、他达拉非与利奥西呱在肺动脉高压中的安全性。荟萃分析仅发现胃肠道障碍在三药间有显著差异,不利于利奥西呱(交互作用P<.01);失衡分析显示利奥西呱视觉障碍报告较少,但胃肠道、出血及肌肉骨骼障碍报告增加。PDE5i与sGC激动剂安全性特征显著不同,因副作用不同而在二者间转换有安全性依据。

要点

  • 利奥西呱胃肠道障碍报告多于西地那非和他达拉非,荟萃分析交互作用P<.01。
  • 利奥西呱视觉障碍报告较少,但出血及肌肉骨骼障碍报告增加。
  • 前庭障碍(头晕)利奥西呱报告更频繁,听力障碍(耳聋)报告较少。

核心结论

  • PDE5i与sGC激动剂在肺动脉高压中的安全性特征显著不同,因副作用不同而在二者间转换有安全性依据。

研究设计与样本

  • 研究结合两种方法:对随机对照试验提取的安全性数据进行荟萃分析,以及对WHO VigiBase个例安全性报告数据库进行失衡分析。

主要发现

  • 荟萃分析中,三药间仅胃肠道障碍存在显著差异,不利于利奥西呱(交互作用P<.01)。
  • 失衡分析中,与西地那非和他达拉非相比,利奥西呱视觉障碍报告较少,胃肠道、出血及肌肉骨骼障碍报告增加。
  • 前庭障碍(头晕)利奥西呱报告更频繁,而听力障碍(耳聋)报告较PDE5i少。

关键数值与推荐

  • 荟萃分析胃肠道障碍交互作用P<.01,不利于利奥西呱。

临床怎么用

  • 因PDE5i与sGC激动剂副作用谱不同,临床可基于安全性考虑在两类药物间转换。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent guidelines recommend riociguat, a soluble guanylate cyclase (sGC) stimulator, and the type 5 phosphodiesterase inhibitor (PDE5i) tadalafil or sildenafil as treatments for pulmonary arterial hypertension. We compared the safety profiles of sildenafil, tadalafil, and riociguat in pulmonary hypertension. METHODS: We combined two approaches. First, we performed a meta-analysis of safety data extracted from randomized controlled trials. Second, we conducted a disproportionality analysis of data from VigiBase, the World Health Organization's global database of individual case safety reports, to compare the safety profiles with real-life data. RESULTS: In the meta-analysis, a significant difference between the three drugs was only detected for gastrointestinal disorders, in disfavor of riociguat (P < .01 for interaction). In the disproportionality analysis, the use of riociguat was associated with fewer reports of visual disorders but increased reporting of gastrointestinal, hemorrhagic, and musculoskeletal disorders compared with sildenafil and tadalafil. Pharmacovigilance signals of hearing/vestibular disorders were heterogeneous: vestibular disorders (dizziness) were reported more frequently for riociguat, whereas hearing disorders (deafness) were reported less frequently compared with PDE5is. CONCLUSIONS: The safety profiles of PDE5is and sGC stimulators significantly differ in pulmonary hypertension. Accordingly, there is a safety rationale in switching between PDE5is and sGC stimulators because of their different side effects. TRIAL REGISTRY: PROSPERO; No.: CRD42016051986; URL: https://www.crd.york.ac.uk/prospero/.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Khouri C, Lepelley M, Roustit M, et al. Comparative Safety of Drugs Targeting the Nitric Oxide Pathway in Pulmonary Hypertension: A Mixed Approach Combining a Meta-Analysis of Clinical Trials and a Disproportionality Analysis From the World Health Organization Pharmacovigilance Database. Chest. 2017. PMID: 29275134. doi:10.1016/j.chest.2017.12.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。